Dr. Peter J. West

About

Dr. Peter J. West is a Research Associate Professor in the Department of Pharmacology and Toxicology at the University of Utah. He earned his B.S. from Lehigh University in 1997 and his Ph.D. from the University of Utah in 2004. His research focuses on the neuropharmacology of synaptic plasticity, learning, and memory in relation to epilepsy, Alzheimer's disease, and Down syndrome. Dr. West is interested in understanding the pathophysiology and treatment of diseases that affect cognition, conducting studies both independently and in collaboration with the Epilepsy Therapy Screening Program, where he is a co-investigator. His work involves developing novel animal models of pharmacoresistant seizures and evaluating the efficacy and cognitive side effects of investigational compounds. His independent research aims to elucidate the molecular and physiological basis of cognitive deficits associated with epilepsy. To this end, he studies synaptic plasticity deficits and cognitive dysfunction in animal models of epilepsy, and his laboratory is developing the first rodent model of pediatric epilepsy due to abnormal hypothalamic development, specifically hypothalamic hamartoma. This research seeks to better understand the developmental origins of gelastic seizures and their associated cognitive impairments. Dr. West’s laboratory employs a variety of techniques, including genetic, electrophysiological, pharmacological, immunohistochemical, and behavioral methods, utilizing specialized…

Research topics

• Medicine
• Gynecology
• Internal medicine
• Oncology

Selected publications

• Correction: Corrigendum: Genome-wide association study of colorectal cancer identifies six new susceptibility loci

  Nature Communications · 2015-10-26 · 9 citations

  erratumOpen access

  Nature Communications 6: Article number:7138 (2015); Published: 7 July 2015; Updated: 26 October 2015 The original version of this Article contained typographical errors in the spelling of the authors Sébastien Küry, Edward L. Giovannucci and Mathieu Lemire, which were incorrectly given as SebastianKury, Edward L.

  PublisherOA PDFDOI

• Population-Based Testing and Treatment Characteristics for Chronic Myelogenous Leukemia.

  PubMed · 2016-01-01 · 7 citations

  article

  INTRODUCTION: National and international hematology/oncology practice guidelines recommend testing for the BCR-ABL mutation for definitive diagnosis of chronic myeloid leukemia (CML) to allow for appropriate treatment with a tyrosine kinase inhibitor (TKI). The purpose of our study was to describe population-based testing and treatment practice characteristics for patients diagnosed with CML. METHODS: We analyzed cases of CML using 2011 data from 10 state registries that are part of the Centers…

  Publisher

• Chemotherapy use and patient treatment preferences in advanced colorectal cancer: A prospective cohort study

  UNC Libraries · 2020-10-30 · 6 citations

  articleOpen access

  Our objective was to determine how patient preferences guide the course of palliative chemotherapy for advanced colorectal cancer.

  PublisherDOI

• Fine-mapping of genome-wide association study-identified risk loci for colorectal cancer in African Americans

  UNC Libraries · 2021-07-01 · 1 citations

  articleOpen access

  Genome-wide association studies of colorectal cancer (CRC) in Europeans and Asians have identified 21 risk susceptibility regions [29 index single-nucleotide polymorphisms (SNPs)]. Characterizing these risk regions in diverse racial groups with different linkage disequilibrium (LD) structure can help localize causal variants. We examined associations between CRC and all 29 index SNPs in 6597 African Americans (1894 cases and 4703 controls). Nine SNPs in eight regions (5q31.1, 6q26-q27, 8q23.3, 8…

  PublisherDOI

• Trans-ethnic genome-wide association study of colorectal cancer identifies a new susceptibility locus in VTI1A

  UNC Libraries · 2020-11-06 · 1 citations

  articleOpen access

  The genetic basis of sporadic colorectal cancer (CRC) is not well explained by known risk polymorphisms. Here we perform a meta-analysis of two genome-wide association studies in 2,627 cases and 3,797 controls of Japanese ancestry and 1,894 cases and 4,703 controls of African ancestry, to identify genetic variants that contribute to CRC susceptibility. We replicate genome-wide statistically significant associations (P < 5×10−8) in 16,823 cases and 18,211 controls of European ancestry. This study…

  PublisherDOI

Recent grants

• NIH Grant R01CA040060

  NIH · $132k · 1989

• NIH Grant R03CA130065

  NIH · $126k · 2010

• NIH Grant N01CN005224

  NIH · $6.7M · 1997

Frequent coauthors

• Leslie Bernstein

  City of Hope

  237 shared

• Katherine L. Kahn

  University of California, Los Angeles

  182 shared

• Jane C. Weeks

  King Edward Memorial Hospital

  172 shared

• S. Yousuf Zafar

  Topiwala National Medical College & BYL Nair Charitable Hospital

  172 shared

• Catarina I. Kiefe

  University of Massachusetts Chan Medical School

  167 shared

• Christina A. Clarke

  Grail (United States)

  164 shared

• Esther M. John

  Public Health Ontario

  163 shared

• Irene L. Andrulis

  Lunenfeld-Tanenbaum Research Institute

  162 shared

Similar researchers at University of Utah

• Randall Petersonh-105
• Karen S. Wilcoxh-42
• Philip J. Moosh-34